- Previous Close
175.93 - Open
178.48 - Bid 176.81 x 200
- Ask 177.38 x 100
- Day's Range
175.81 - 178.97 - 52 Week Range
93.95 - 219.34 - Volume
120,467 - Avg. Volume
258,528 - Market Cap (intraday)
5.088B - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
44.84 - EPS (TTM)
3.95 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
207.22
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: KRYS
View More
Performance Overview: KRYS
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRYS
View MoreValuation Measures
Market Cap
5.05B
Enterprise Value
4.50B
Trailing P/E
44.54
Forward P/E
25.38
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
31.13
Price/Book (mrq)
6.03
Enterprise Value/Revenue
27.09
Enterprise Value/EBITDA
37.52
Financial Highlights
Profitability and Income Statement
Profit Margin
63.73%
Return on Assets (ttm)
0.31%
Return on Equity (ttm)
14.20%
Revenue (ttm)
166.23M
Net Income Avi to Common (ttm)
105.94M
Diluted EPS (ttm)
3.95
Balance Sheet and Cash Flow
Total Cash (mrq)
559.61M
Total Debt/Equity (mrq)
0.92%
Levered Free Cash Flow (ttm)
-26.91M
Research Analysis: KRYS
View MoreCompany Insights: KRYS
KRYS does not have Company Insights
Research Reports: KRYS
View MoreRaising target price to $191.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $191.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $199.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $199.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $194.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $194.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $208.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $208.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target